Compare RVYL & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVYL | AIMD |
|---|---|---|
| Founded | 2007 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 10.9M |
| IPO Year | N/A | N/A |
| Metric | RVYL | AIMD |
|---|---|---|
| Price | $0.28 | $2.15 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.5M | 37.1K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,858,000.00 | $113,037.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $297.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 29.50 | ★ 178.19 |
| 52 Week Low | $0.25 | $1.78 |
| 52 Week High | $2.33 | $5.00 |
| Indicator | RVYL | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 41.95 | 40.41 |
| Support Level | $0.31 | $2.12 |
| Resistance Level | $0.35 | $2.29 |
| Average True Range (ATR) | 0.03 | 0.17 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 1.91 | 24.07 |
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.
Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.